Last updated: July 17, 2026

Application No. 18/417,787

BRAIN TARGETING COMPOSITIONS AND METHODS OF USE THEREOF

Non-Final OA

Filed

Jan 19, 2024

Priority

Jul 22, 2021 — provisional 63/224,848 +2 more

Examiner

BUTTICE, AUDREY L

Art Unit

1647

Tech Center

1600 — Biotechnology & Organic Chemistry

Assignee

Genentech Inc.

OA Round

1 (Non-Final)

This examiner grants 46% of cases after interview

— +24.4% interview lift. A telephonic interview to clarify the technical implementation could significantly improve the outcome.

Based on 136 resolved cases, 2023–2026

Examiner Intelligence

BUTTICE, AUDREY L View full profile →

Grants 46% of resolved cases

Career Allowance Rate

62 granted / 136 resolved

-14.4% vs TC avg

Strong +24% interview lift

Without

With

+24.4%

Interview Lift

resolved cases with interview

Typical timeline

3y 4m

Avg Prosecution

37 currently pending

Career history

195

Total Applications

across all art units

Statute-Specific Performance

§103

64.3%

+24.3% vs TC avg

§102

1.2%

-38.8% vs TC avg

§112

6.7%

-33.3% vs TC avg

Black line = Tech Center average estimate • Based on career data from 136 resolved cases

Prosecution Timeline

Jan 19, 2024

Application Filed

May 07, 2026

Non-Final Rejection mailed (current)

Precedent Cases

Applications granted by this same examiner with similar technology

16/652,413

Patent 12673110

USE OF ANTI-HER2 ANTIBODY-DRUG CONJUGATE IN TREATING UROTHELIAL CARCINOMA

6y 3m to grant Granted Jul 07, 2026

16/485,777

Patent 12667557

METHOD FOR TREATING EGFR-TKI-RESISTANT NON-SMALL CELL LUNG CANCER BY ADMINISTRATION OF ANTI-HER3 ANTIBODY-DRUG CONJUGATE

6y 10m to grant Granted Jun 30, 2026

18/015,776

Patent 12655193

HLA CLASS II-RESTRICTED DRB T CELL RECEPTORS AGAINST RAS WITH G12D MUTATION

3y 5m to grant Granted Jun 16, 2026

17/430,704

Patent 12637504

HUMANIZED ANTIBODY AND METHOD FOR USING THE SAME

4y 9m to grant Granted May 26, 2026

17/825,800

Patent 12637689

mRNA CONSTRUCT FOR PROTEIN EXPRESSION AND USE OF SAME

4y 0m to grant Granted May 26, 2026

Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.

Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2

Expected OA Rounds

46%

Grant Probability

70%

With Interview (+24.4%)

3y 4m (~10m remaining)

Median Time to Grant

Low

PTA Risk

Based on 136 resolved cases by this examiner. Grant probability derived from career allowance rate.